|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 550.5 SEK | -1.70% |
|
-2.91% | +2.32% |
| 01:18pm | Camurus' Rare Growth Disorder Drug Accepted for Review in EU | MT |
| May. 08 | Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024 |
Camurus AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 389.99 million compared to SEK 284.04 million a year ago. Net income was SEK 77.86 million compared to SEK 58.83 million a year ago.
Basic earnings per share from continuing operations was SEK 1.36 compared to SEK 1.06 a year ago. Diluted earnings per share from continuing operations was SEK 1.32 compared to SEK 1.02 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.32% | 3.01B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
CAMURUS AB 
